CDKN1A and ovarian carcinoma: In this study, bexarotene upregulated CDKN1A, which codes a cyclin-dependent kinase inhibitor p21, and downregulated cell cycle-related proteins downstream of p21.Therefore, bexarotene also acts as an RXR agonist in ovarian cancer cells.